EQL Pharma AB (publ) announced unaudited consolidated and nonconsolidated earnings results for the first quarter ended March 31, 2017. For the first quarter, the group's net sales were SEK 5,324,000 against SEK 12,874,000 a year ago. EBITDA was SEK 339,000 against SEK 3,995,000 a year ago. EBIT was SEK 84,000 against SEK 3,638,000 a year ago. Net profit for the period was SEK 84,000 against SEK 3,633,000 a year ago. Cash flow from operating after change in working capital was SEK 1,715,000 against SEK 1,337,000 a year ago.

For the first quarter, the parent company's net sales were SEK 4,018,000 against SEK 12,874,000 a year ago. LBITDA was SEK 312,000 against EBITDA of SEK 4,196,000 a year ago. LBIT was SEK 557,000 against EBIT of SEK 3,839,000 a year ago. Net loss for the period was SEK 557,000 against net profit for the period of SEK 3,834,000 a year ago. Cash flow from operating after change in working capital was SEK 757,000 against SEK 1,284,000 a year ago.

For the year, the company expects to growing profitability at least at the same rate as sales growth. The growth will be distributed unevenly over the 5-year period. Due to the temporary withdrawal for EQL Hydroxyzine from the market, sales for 2017 are expected to be around SEK 4 million to SEK 5 million lower than in 2016. Therefore, the profit for 2017 is expected to decline to around negative SEK 2 million for the year.